Impaired interferon-γ production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma

Blood

Volumn 106, Issue 3, 2005, Pages 963-970

  Robertson, Michael J ^a   Chang, Hua Chen ^b   Pelloso, David ^b   Kaplan, Mark H ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT4 PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TH2 CELL;

EID: 23044498580     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0201     Document Type: Article

References (60)

1. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol. 1995;13;2656-2675.
2. McKean-Cowdin R, Feigelson HS, Ross RK, Pike MC, Henderson BE. Declining cancer rates in the 1990s. J Clin Oncol. 2000;18:2258-2268.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
4. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10: 116-127.
5. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997;89:814-822.
6. Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial. J Clin Oncol. 2002;20:467-475.
7. Klingemann H-G, Phillips GL. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant. 1991;8:73-81.
8. Benyunes MC, Higuchi CM, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. 1995;16:283-288.
9. Davis TA, Hsu FJ, Caspar CB, et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant. 20017:517-522.
10. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777-783.
11. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13: 251-276.
12. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178: 1223-1230.
13. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153:1697-1706.
14. Zou J-P, Yamamoto N, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol. 1995;7:1135-1145.
15. Mu J, Zou J-P, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;55: 4404-4408.
16. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother. 1995;17:71-77.
17. + T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J Immunol. 2003;170:400-412.
18. Leonard WJ, O'Shea JJ. JAKS and STATS: biological implications. Annu Rev Immunol. 1998;16: 293-322.
19. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin- 12 receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521.
20. Kaplan MH, Sun Y-L, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996;382:174-177.
21. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382:171-174.
22. Robertson MJ, Pelloso D, Abonour R, et al. Interleukin-12 immunotherapy after autologous stem cell transplantation for hematologic malignancies. Clin Cancer Res. 2002;8:3383-3393.
23. Pelloso D, Cyran K, Timmons L, Williams BT, Robertson MJ. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation. Clin Cancer Res. 2004; 10:1935-1942.
24. + cell doses in stem cell products is associated with inferior progression-free survival after autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma [abstract]. Blood. 2003;102:987a.
25. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J. Human natural killer cell adhesion molecules: differential expression after activation and participation in cytoiysis. J Immunol. 1990;145: 3194-3201.
26. Chang H-C, Zhang S, Oldham I, Naeger L, Hoey T, Kaplan MH. STAT4 requires the N-terminal domain for efficient phosphorylation. J Biol Chem. 2003;278:32471-32477.
27. Roberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation, and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1993;12: 469-475.
28. Koehne G, Zeller W, Stockschlaeder M, Zander AR. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:149-156.
29. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92:1471-1490.
30. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983-3988.
31. + cells: a naturally occurring population of regulatory T cells. Blood. 2001;98:2736-2744.
32. + T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294.
33. + T cells with IFN-γ-dependent anti-angiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171:5931-5939.
34. Kaplan MH, Grusby MJ. Regulation of T helper cell differentiation by STAT molecules. J Leukoc Biol. 1998;64:2-5.
35. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383: 787-793.
36. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity. 1995;2:665-675.
37. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
38. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875-883.
39. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277:2005-2007.
40. Nanki T, Lipsky PE. Lack of correlation between chemokine receptor and Th1/TH2 cytokine expression by individual memory T cells. Int Immunol. 2000;12:1659-1667.
41. Wang KS, Frank DA1 Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000;95:3183-3190.
42. Wang KS, Zorn E, Ritz J. Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood. 2001;97:3860-3866.
43. Visconti R, Gadina M, Chiariello M, et al. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood. 2000;96:1844-1852.
44. Zhang S, Kaplan MH. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-γ expression. J Immunol. 2000;165:1375-1380.
45. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45β required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat Immunol. 2001;2:157-164.
46. Yu W-G, Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol. 1996;8: 855-865,
47. Yang Y-G, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997;90:4651-4660.
48. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol. 2001;166:6555-6563.
49. Winter H, Hu H-M, McClain K, Urba WJ, Fox BA. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol. 2001;166:7370-7380.
50. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
51. bright subset. Blood. 2001; 97:3146-3151.
52. Mavropoulos A, Sully G, Cope AP, Clark A. Stabilization of IFN-γ mRNA by MARK p38 in IL-12-and IL-18-stimulated human NK cells. Blood. 2004;105:282-288.
53. Voss SD, Daley J, Ritz J, Robertson MJ. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998;160:1618-1626.
54. + T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998;102:561-575.
55. Lawless VA, Zhang S, Ozes ON, et al. Stat4 regulates multiple components of IFN-γ-inducing signaling pathways. J Immunol. 2000;165:6803-6808.
56. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992;79:517-526.
57. Miller JS, Tessmer-Tuck J, Pierson BA, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant. 1997;3:34-44.
58. Gollob JA, Veenstra KG, Parker RA. et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell cancer. J Clin Oncol. 2003;21:2564-2573.
59. Robertson MJ, Mier J, Weisenbach J, et al. A phase I dose escalation study to assess safety and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in adult patients with solid tumors [abstract 713]. Proc Am Soc Clin Oncol. 2003;22: 178.
60. Robertson MJ, Mier J, Logan T, et al. Tolerability and anti-tumor activity of recombinant human IL-18 administered as five daily intravenous infusions in patients with solid tumors [abstract 2553]. J Clin Oncol. 2004;22:176s.